Document Detail


Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
MedLine Citation:
PMID:  20085937     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) with demonstrated efficacy in combination with carboplatin and paclitaxel (PCB) for the treatment of advanced non-small-cell lung cancer (NSCLC). Administration of bevacizumab is postulated to decrease nitric oxide synthesis and lead to hypertension, which may be a physiological sign that the VEGF pathway is more actively being blocked and could result in improved outcomes. PATIENTS AND METHODS Eastern Cooperative Oncology Group (ECOG) 4599 randomly assigned patients with nonsquamous NSCLC to carboplatin and paclitaxel (PC) versus PCB. Hypertensive patients were compared with nonhypertensive patients with respect to overall survival (OS) and progression-free survival (PFS) using blood pressure data and adverse event data separately. High blood pressure (HBP) by the end of cycle 1 was defined as blood pressure > 150/100 at any previous time or at least a 20-mmHg increase in diastolic blood pressure from baseline. Results In a multivariable Cox model adjusting for HBP as a time-varying covariate, comparing those on PCB with HBP with those on PC gave an OS hazard ratio (HR) of 0.60 (95% CI, 0.43 to 0.81; P = .001); comparing those on PCB without HBP with those on PC alone, the OS HR was 0.86 (95% CI, 0.74 to 1.00; P = .05). Comparing the PCB HBP group with PC gave an adjusted PFS HR of 0.54 (95% CI, 0.41 to 0.73; P < .0001) and comparing those on PCB without HBP to those on PC, the HR was 0.72 (95% CI, 0.62 to 0.84; P < .0001). The 6-month cumulative incidence of hypertension was 6.2% (95% CI, 3.9% to 8.6%). CONCLUSION Data from ECOG 4599 suggest that onset of HBP during treatment with PCB may be associated with improved outcomes, and additional studies of the downstream effects of VEGF suppression and hypertension are needed.
Authors:
Suzanne E Dahlberg; Alan B Sandler; Julie R Brahmer; Joan H Schiller; David H Johnson
Related Documents :
2913777 - Prazosin in hypertensive patients with chronic bronchitis and asthma: a brief report.
9645977 - Carotid endarterectomy does not affect long-term blood pressure: observations from the ...
6629457 - When and how far should we lower blood pressure?
10662747 - The pressor response to water drinking in humans : a sympathetic reflex?
3038667 - The effects of parenteral injections of adenosine and its analogs on blood pressure and...
18692247 - The retinal vasculature as a fractal: methodology, reliability, and relationship to blo...
Publication Detail:
Type:  Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural     Date:  2010-01-19
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  28     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-19     Completed Date:  2010-03-23     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  949-54     Citation Subset:  IM    
Affiliation:
Department of Biostatistics and Computational Biology, CLSB 11007, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA. dahlberg@jimmy.harvard.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Blood Pressure / drug effects
Carboplatin / administration & dosage
Carcinoma, Non-Small-Cell Lung / drug therapy*,  mortality,  secondary
Disease-Free Survival
Female
Humans
Hypertension / chemically induced*,  drug therapy
Lung Neoplasms / drug therapy*,  mortality,  pathology
Male
Neoplasm Staging
Paclitaxel / administration & dosage
Prognosis
Survival Rate
Treatment Outcome
Grant Support
ID/Acronym/Agency:
CA23318/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab; 33069-62-4/Paclitaxel; 41575-94-4/Carboplatin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphopr...
Next Document:  The PI3K pathway as drug target in human cancer.